RISK FACTORS OF HIV/DR-TB CO-INFECTION AMONG PATIENTS MANAGED AT NIGERIAN TREATMENT CENTERS: ANALYSIS OF NIGERIAN TUBERCULOSIS REFERENCE LABORATORY DATA, ZARIA, 2017

Ado U. Adamu, M. B. Sufiyan, S. Ahmed, Umar Faruk Abubakar

Abstract


HIV and Mycobacterium tuberculosis (MTB) co-infection constitutes serious public health challenge in many parts of the world including, Africa. To date, HIV/MDR-TB prevalence is estimated by the National Tuberculosis and Leprosy Control Program (NTBLCP) based on existing HIV/TB surveillance data, which lack   accuracy due to questionable quality of the routine surveillance information, completeness of TB notification and instances of TB under-diagnosis. Data from Laboratory register of MDR-TB patients sent for TB culture and DST at the National TB reference Laboratory of the NTBLTC, Zaria were reviewed from January 1 to December 31, 2017. HIV/MDR- TB was defined as co-infection as any person with positive laboratory HIV and MDR- TB test. Data were analyzed using descriptive statistics and logistics regression model (α = 0.05). Prevalence of HIV/MDR-TB co-infection was 92(17.0%). Almost half of all the HIV/MDR-TB co- infection falls within the age group 20 – 59 years among all sexes. The likelihood of having HIV/MDR-TB co-infection was 1.8 (OR 1.8: CI = 1.1 – 2.8; p = 0.024) times higher among females than male’s patients. HIV/MDR-TB co-infection rate was high in National Tuberculosis Reference Laboratory data, Zaria and it was found to be more prevalent among the most economically important age group, hence exerting a negative impact on Nigeria’s economy. The study recommended that the NTBLCP implement measures that will improve adherence to prevention and control practices across the country.


Keywords


Tuberculosis; TB/HIV Co-infection; treatment outcome; Mortality; Risk factors.

Full Text:

PDF

References


Adejumo OA, Daniel OJ, Otesanya AF, Adegbola AA, Femi- T. 2017. Factors associated with TB/HIV co-infection among drug sensitive tuberculosis patients managed in a secondary health facility In Lagos , Nigeria. Department of Community Health and Primary Health Care , Lagos State University Teaching Hospital , Ikeja. 2017;11:75–82.

Gao L, Zhou F, Li X, Jin Q (2010). HIV / TB Co-Infection in Mainland China : A Meta-Analysis. 2010;5(5).

Wingfield C, Lange C, Migliori GB, Kritski AL, Meyerhans A. (2010). Challenges and perspectives for improved management of HIV/ Mycobacterium tuberculosis co-infection ´,. 2010;36(6):1242–7

Breen RAM, Swaden L, Ballinger J, Lipman MCI. Tuberculosis and HIV Co-Infection A Practical Therapeutic Approach. Ther Pract. 2006;66(18):2299–308.

Martin E, Rottenberg ME. Tuberculosis and HIV Co-Infection. 2012;

Co-infection PTB, State N, Amuta EU, Isaac T, Akyala M. A Retrospective Study on the Epidemiological Trend of Human Immunodeficiency Virus ( HIV ) and Pulmonary Tuberculosis. 2013;3(7):45–52.

Govenment F. National HIV Sero-Prevalence Sentinel Survey 2008 Metadata Production. 2012;

Nigeria F ministry of health (FMOH). FIRST National Report TB Prevalence Survey 2012, Nigeria. 2012.

World Health Organization (WHO). WHO treatment guidelines for drug- resistant tuberculosis 2016. The End TB Strategy (2016 Update). 2016.

Odaibo GN, Okonkwo P, Lawal OM, Olaleye DO. HIV Infection among Newly Diagnosed TB Patients in Southwestern Nigeria : A Multi-DOTS Center Study *. 2013;2013(June):154–9.

DEPARTMENT OF PUBLIC HEALTH & LEPROSY CONTROL PROGRAMME Nigeria 2014 NTBLCP Annual Report. 2014;

WHO. Control of epidemic meningococcal disease. WHO practical guidelines. Int Organ [Internet]. 1997;17:82. Available from: http://www.who.int/emc

World Health Organisation. Multidrug and extensively drug-resistant TB. Indian J Tuberc [Internet]. 2010;57(4):180–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21141336

Cabibbe AM, Miotto P, Moure R, Alcaide F, Feuerriegel S, Pozzi G, et al. Lab-on-Chip-Based Platform for Fast Molecular Diagnosis of Multidrug-Resistant Tuberculosis. 2015;53(12).

Mo I, Eo O, Gc M, B VW, Hp H, Dh A, et al. Factors Associated with Prevalent Tuberculosis Among Patients Receiving Highly Active Antiretroviral Therapy in a Nigerian Tertiary Hospital. 2016;120–8.No Journal name????

Babatunde OA. Factors Affecting Treatment Outcomes of Tuberculosis in a Tertiary Health Center in Southwestern Nigeria. 2013;4(2):209–18.

Tweya H, Feldacker C, Phiri S, Ben-smith A, Fenner L, Jahn A, et al. Comparison of Treatment Outcomes of New Smear- Positive Pulmonary Tuberculosis Patients by HIV and Antiretroviral Status in a TB / HIV Clinic , Malawi. 2013;8(2).

Daniel OJ, Adejumo OA, Abdulrrazzaq HA. Implementation of the Revised Guideline on TB / HIV Collaborative Activities in Lagos , Nigeria. 2015;9(January 2013):1–7.

Article A. Mortality , TB / HIV co-infection , and treatment dropout : predictors of tuberculosis prognosis in Recife , Pernambuco State , Brazil Mortalidade , co-infecção por HIV / AIDS e abandono do tratamento como fatores prognósticos para tuberculose em Recife ,. 2008;24(4):887–96.

National Tuberculosis and Leprosy control Program Algorithm for TB Screening , Diagnosis and Management. 2017;(June):2017.


Refbacks

  • There are currently no refbacks.


 

 

 ISSN: 3026-9474 (Online)

 

   

 

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.